Scinai Immunotherapeutics (SCNI) has released an update.
Scinai Immunotherapeutics Ltd. is advancing in the biopharmaceutical market with their innovative alpaca-derived nanosized antibodies (NanoAbs), targeting large markets with unmet medical needs. With a robust pipeline that includes potential treatments for psoriasis and COVID-19, the company is leveraging its end-to-end boutique CDMO services and collaboration with renowned institutes to accelerate its drug development process. The company’s unique approach to antibody development promises significant clinical and commercial advantages, including lower costs, improved patient safety, and convenience.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.
